What changed
Rani Therapeutics reported Q3 FY26 revenue of $2M, driven by $1.7M in contract revenue tied to the Chugai collaboration versus none in the prior-year period. Net income came in at -$9M, with net loss widening to $8.8M from $7.9M a year ago as R&D expenses rose to $6.0M from $3.2M on higher compensation costs.
Why it matters
Rani Therapeutics reported Q3 FY26 revenue of $2M, driven by $1.7M in contract revenue tied to the Chugai collaboration versus none in the prior-year period. Net income came in at -$9M, with net loss